More on bevacizumab in hereditary hemorrhagic telangiectasia

N Engl J Med. 2009 Aug 27;361(9):931; author reply 931-2. doi: 10.1056/NEJMc091271.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Humans
  • Male
  • Middle Aged
  • Telangiectasia, Hereditary Hemorrhagic / drug therapy*
  • Vascular Endothelial Growth Factor A / immunology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab